Substance / Medication

Resorcinol

Overview

Active Ingredient
resorcinol
RxNorm CUI
35382

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

123 trials linked to this intervention

123
Total Trials
6
Recruiting
78
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Isobutylamido Thiazolyl Resorcinol (Thiamidol) for Combatting Hyperpigmentation: A Systematic Review of Clinical Studies.
Klein Paytra A, Kincaid Colin, Babadjouni Arash et al. · J Drugs Dermatol · 2024
PMID: 39496126Meta-Analysis
Plasma Alkylresorcinols Is an Objective Biomarker for Gluten Intake in Young Children.
Af Segerstad Elin M Hård, Ericson-Hallström Emelie, Bokström Anna et al. · J Nutr · 2025
PMID: 39880171RCTFull text (PMC)
Efficacy of isobutylamido thiazolyl resorcinol for prevention of laser-induced post-inflammatory hyperpigmentation: A randomized, controlled trial.
Vachiramon Vasanop, Sakpuwadol Nawara, Yongpisarn Tanat et al. · J Cosmet Dermatol · 2024
PMID: 38497328RCT
Superior even skin tone and anti-ageing benefit of a combination of 4-hexylresorcinol and niacinamide.
Shariff Rezwan, Du Yaping, Dutta Maitreyee et al. · Int J Cosmet Sci · 2022
PMID: 34958693RCTFull text (PMC)
Clinical efficacy and safety of nano-microneedle-assisted phenylethyl resorcinol for the treatment of infraorbital dark circles.
Yu Cheng-Qian, Xu Xue-Gang, Chen Hong-Duo et al. · J Cosmet Dermatol · 2021
PMID: 32783330RCT
Isobutylamido thiazolyl resorcinol for prevention of UVB-induced hyperpigmentation.
Vachiramon Vasanop, Kositkuljorn Chaninan, Leerunyakul Kanchana et al. · J Cosmet Dermatol · 2021
PMID: 32757247RCT
Simplified method for the measurement of plasma alkylresorcinols: Biomarkers of whole-grain intake.
Rodríguez-Morató Jose, Jayawardene Sarah, Huang Neil K et al. · Rapid Commun Mass Spectrom · 2020
PMID: 32297383RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Resorcinol (substance)
SNOMED CT
78032005
UMLS CUI
C0073085
RxNorm CUI
35382

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
123
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.